Birgit Schoeberl

4.7k citations

44 papers · 3.3k indexed · 1 hit paper · h-index 21

Oncology top 2%
- HER2/EGFR in Cancer Research 18
Molecular Biology top 5%
- Glycosylation and Glycoproteins Research 7
- PI3K/AKT/mTOR signaling in cancer 7
- Gene Regulatory Network Analysis 6
- Viral Infectious Diseases and Gene Expression in Insects 4
- Bioinformatics and Genomic Networks 4
Radiology, Nuclear Medicine and Imaging top 2%
- Monoclonal and Polyclonal Antibodies Research 16
Modeling and Simulation top 2%
Computational Theory and Mathematics top 1%
- Computational Drug Discovery Methods 9

Co-authors: Ulrik B. Nielsen Claudia Eichler-Jonsson Ernst Dieter Gilles Gertraud Müller Peter K. Sorger Jonathan B. Fitzgerald Mario Niepel Brian D. Harms
Cited by: Oncology Molecular Biology Radiology, Nuclear Medicine and Imaging
Journals: Cancer Research (8 papers)Science Signaling (3 papers)Molecular Cancer Therapeutics (3 papers)
Partner nations: United States Germany Switzerland

In The Last Decade

Birgit Schoeberl

41 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Birgit Schoeberl

Since Specialization

Citations

This map shows the geographic impact of Birgit Schoeberl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgit Schoeberl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgit Schoeberl more than expected).

Fields of papers citing papers by Birgit Schoeberl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgit Schoeberl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgit Schoeberl. The network helps show where Birgit Schoeberl may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Birgit Schoeberl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Birgit Schoeberl Line = papers co-authored together Birgit Schoeberl links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles International Journal of Molecular Sciences ·T. Tusoboi,Michael A. Huston,Rolland Bantar Tata,Birgit Schoeberl,Özlem Taştan Bishop	2023	13
2	Ten simple rules to power drug discovery with data science PLoS Computational Biology ·Enrico Ferrero,Sophie Brachat,Jeremy L. Jenkins,Philippe Marc,Peter Skewes-Cox,Robert C. Altshuler,Caroline Gubser Keller,Audrey Kauffmann,Olga Shabalin,Jason M. Laramie,Birgit Schoeberl,Mark L. Borowsky,Nikolaus Stiefl	2020	10
3	Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer Clinical Cancer Research ·Carly Livingston Zacarías Copar,Emily A. Pace,Sharlene Adams,Michael D. Curley,Victoria Rimkunas,Lin Nie,Jeffrey C Webster,Troy Bloom,Sergio Iadevaia,Jason Baum,王之钧李福辰郭昱涛,Akos Czibere,Chrystal U. Louis,Daryl C. Drummond,Ulrik B. Nielsen,Birgit Schoeberl,J. Marc Pipas,Robert M. Straubinger,Vasileios Askoxylakis,Alexey A. Lugovskoy	2018	44
4	Modeling chemotherapy-induced stress to identify rational combination therapies in the DNA damage response pathway Science Signaling ·Ozan Alkan,Birgit Schoeberl,Carlo Daffonchio,Alexander Koshkaryev,Tim Heinemann,Daryl C. Drummond,Michael B. Yaffe,Andreas Raue	2018	19
5	Analysis of growth factor signaling in genetically diverse breast cancer lines BMC Biology ·Mario Niepel,Marc Hafner,Emily A. Pace,Mirra Chung,Diana H. Chai,Lili Zhou,Jeremy L. Muhlich,Birgit Schoeberl,Peter K. Sorger	2014	32
6	MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors Molecular Cancer Therapeutics ·Jonathan B. Fitzgerald,Bryan W. Johnson,Jason Baum,Sharlene Adams,Sergio Iadevaia,Jian Tang,Victoria Rimkunas,Lihui Xu,Neeraj Kohli,Rachel Rennard,Albert Gyorgy Borbely,Yang Jiao,Brian D. Harms,Kenneth J. Olivier,Birgit Schoeberl,Ulrik B. Nielsen,Alexey A. Lugovskoy	2013	87
7	Dexamethasone can rescue cytokine-induced chondrocyte apoptosis in bovine and human cartilage Osteoarthritis and Cartilage ·Issa John Gbla,Κ. Μάντζιαρης,Paul W. Kopesky,Susan Chubinskaya,Birgit Schoeberl,Alan J. Grodzinsky	2013	2
8	Single timepoint models of dynamic systems Interface Focus ·Karen Sachs,Valeriy P. Popkov,Jonathan B. Fitzgerald,Birgit Schoeberl,Garry P. Nolan,Claire J. Tomlin	2013	6
9	Rapid optimization and prototyping for therapeutic antibody-like molecules mAbs ·Lihui Xu,Neeraj Kohli,Rachel Rennard,Yang Jiao,Albert Gyorgy Borbely,Kathy Zhang,Jason Baum,Bryan W. Johnson,Jian Tang,Birgit Schoeberl,Jonathan B. Fitzgerald,Ulrik B. Nielsen,Alexey A. Lugovskoy	2013	21
10	Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies Molecular Cancer Therapeutics ·Yu Zhou,KP Thai,Brian D. Harms,Hao Zou,Jianlong Lou,Fraser Conrad,Gregory P. Adams,Birgit Schoeberl,Ulrik B. Nielsen,James D. Marks	2012	54
11	Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 Molecular Cancer Therapeutics ·Charlotte F. McDonagh,Alexandra Huhalov,Brian D. Harms,Sharlene Adams,Violette Paragas,Youngjae Choe,Bo Zhang,Lia Luus,Ryan Overland,Stephanie A. Nguyen,Jinming Gu,Neeraj Kohli,Wilson João Cunico Filho,Michael J. Feldhaus,Arthur J. Kudla,Birgit Schoeberl,Ulrik B. Nielsen	2012	222
12	An expanding role for cell biologists in drug discovery and pharmacology Molecular Biology of the Cell ·Peter K. Sorger,Birgit Schoeberl	2012	14
13	Optimizing Properties of Antireceptor Antibodies Using Kinetic Computational Models and Experiments Methods in enzymology on CD-ROM/Methods in enzymology ·Brian D. Harms,Jeffrey D. Kearns,Stephen Su,Neeraj Kohli,Ulrik B. Nielsen,Birgit Schoeberl	2011	22
14	An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation Cancer Research ·Birgit Schoeberl,Anthony C. Faber,Danan Li,Mei‐Chih Liang,Katherine Crosby,Matthew Onsum,Olga Burenkova,Emily Pace,Zandra E. Walton,Lin Nie,Андрій Олександрович ТИМКІВ,Youngchul Song,Ulrik B. Nielsen,Jeffrey A. Engelman,Kwok‐Kin Wong	2010	215
15	An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells Cancer Cell ·Qing Sheng,Xinggang Liu,Eleanor Fleming,Karen Yuan,Huiying Piao,Jinyun Chen,J. Roche,Roman K. Thomas,Heidi Greulich,Anna C. Schinzel,Sara Zaghlul,David Batt,Seth A. Ettenberg,Matthew Meyerson,Birgit Schoeberl,Andrew L. Kung,William C. Hahn,Ronny Drapkin,David M. Livingston,Joyce F. Liu	2010	178
16	Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data Molecular Systems Biology ·William W. Chen,Birgit Schoeberl,Paul Jasper,Mario Niepel,Ulrik B. Nielsen,Douglas A. Lauffenburger,Peter K. Sorger	2009	276
17	A Data-Driven Computational Model of the ErbB Receptor Signaling Network PubMed ·Birgit Schoeberl,Emily Pace,Juan Xavier Vargas,Andrés González Medina,Federico Solórzano-Torrejano,Peter K. Sorger,Ulrik B. Nielsen	2006	7
18	Systems biology and combination therapy in the quest for clinical efficacy Nature Chemical Biology ·Jonathan B. Fitzgerald,Birgit Schoeberl,Ulrik B. Nielsen,Peter K. Sorger	2006	439
19	Control of MAPK signalling: from complexity to what really matters Oncogene ·Jorrit J. Hornberg,Bernd R. Binder,Frank J. Bruggeman,Birgit Schoeberl,Reinhart Heinrich,Hans V. Westerhoff	2005	148
20	Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptorsbreakdown → Nature Biotechnology ·Birgit Schoeberl,Claudia Eichler-Jonsson,Ernst Dieter Gilles,Gertraud Müller	2002	726

About Birgit Schoeberl

Birgit Schoeberl is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Computational Theory and Mathematics, having authored 44 papers that have together received 3.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), Computational Drug Discovery Methods (9 papers), Glycosylation and Glycoproteins Research (7 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Gene Regulatory Network Analysis (6 papers), Viral Infectious Diseases and Gene Expression in Insects (4 papers) and Bioinformatics and Genomic Networks (4 papers). The work is most often cited by research in Oncology (1.1k citations), Molecular Biology (2.4k citations) and Radiology, Nuclear Medicine and Imaging (785 citations). Birgit Schoeberl has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Ulrik B. Nielsen, Claudia Eichler-Jonsson, Ernst Dieter Gilles, Gertraud Müller, Peter K. Sorger, Jonathan B. Fitzgerald, Mario Niepel, Brian D. Harms, Neeraj Kohli and Paul Jasper. Their work appears in journals such as Cancer Research, Science Signaling, Molecular Cancer Therapeutics, Osteoarthritis and Cartilage and PLoS Computational Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact